DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b

Approved direct antiviral agent (DAA) combinations are associated with high rates of sustained virological response (SVR) and the absence of a detectable hepatitis C viral load 12–24 weeks after treatment discontinuation. However, a low percentage of individuals fail DAA therapy. Here, we report the...

Descripción completa

Detalles Bibliográficos
Autores principales: De Francesco, Maria Antonia, Gargiulo, Franco, Zaltron, Serena, Spinetti, Angiola, Castelli, Francesco, Caruso, Arnaldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517502/
https://www.ncbi.nlm.nih.gov/pubmed/36141921
http://dx.doi.org/10.3390/ijerph191811655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517502/
https://www.ncbi.nlm.nih.gov/pubmed/36141921
http://dx.doi.org/10.3390/ijerph191811655

Ejemplares similares